Lisuride plus selegiline in the treatment of early Parkinson's disease

Lisuride plus selegiline in the treatment of early Parkinson's disease We treated 20 early Parkinson's disease subjects with the dopamine agonist lisuride in combination with the MAO‐B inhibitor selegiline (L‐deprenyl). We started with lisuride alone for one month, then we added selegiline versus placebo to lisuride in double‐blind conditions for 3 months; finally all patients received lisuride and selegiline for another 3 months. Lisuride alone (1.43 ± 0.10 mg) significantly improved PD. When selegiline (10 mg/day) was added in the double‐blind phase the mean lisuride dosage could be reduced by 22.8% without deterioration of the clinical effects, and the same occurred in the former placebo group when selegiline was added. The combination of both drugs was well tolerated. These data are of interest for the interpretation of the effects of selegiline. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Neurologica Scandinavica Wiley

Lisuride plus selegiline in the treatment of early Parkinson's disease

Loading next page...
 
/lp/wiley/lisuride-plus-selegiline-in-the-treatment-of-early-parkinson-s-disease-COASXyQlp7
Publisher
Wiley
Copyright
Copyright © 1991 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0001-6314
eISSN
1600-0404
D.O.I.
10.1111/j.1600-0404.1991.tb03973.x
Publisher site
See Article on Publisher Site

Abstract

We treated 20 early Parkinson's disease subjects with the dopamine agonist lisuride in combination with the MAO‐B inhibitor selegiline (L‐deprenyl). We started with lisuride alone for one month, then we added selegiline versus placebo to lisuride in double‐blind conditions for 3 months; finally all patients received lisuride and selegiline for another 3 months. Lisuride alone (1.43 ± 0.10 mg) significantly improved PD. When selegiline (10 mg/day) was added in the double‐blind phase the mean lisuride dosage could be reduced by 22.8% without deterioration of the clinical effects, and the same occurred in the former placebo group when selegiline was added. The combination of both drugs was well tolerated. These data are of interest for the interpretation of the effects of selegiline.

Journal

Acta Neurologica ScandinavicaWiley

Published: Jun 1, 1991

References

  • Bromocriptine and lisuride in Parkinson's disease
    Lleberman, Lleberman; Gopinathan, Gopinathan; Neophytides, Neophytides; Leibowitz, Leibowitz; Walker, Walker; Hiesiger, Hiesiger
  • Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease
    Stern, Stern; Hardie, Hardie; Sandler, Sandler
  • Selegiline in the treatment of Parkinson's disease ‐ Long‐term experience
    Yahr, Yahr; Elizan, Elizan; Moros, Moros

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off